Tagraxofusp is a first-in-class CD123 fusion protein that is approved for treatment in Blastic Plasmacytoid Dendritic Cell Neoplasm.
| SparkCures ID | 234 |
|---|---|
| Developed By | Stemline Therapeutics, Inc. |
| Brand Name | Elzonris® |
| Generic Name | Tagraxofusp |
| Additional Names | SL-401 |
| Treatment Targets |
There are no resources, links or videos to display for this treatment.